SCHEMBL23094635

SCHEMBL23094635

CSc1ncncc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.42
KDM4A O75164 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
HIF1AN Q9NWT6 1/20 0.42
KDM2A Q9Y2K7 1/20 0.42
HCAR2 Q8TDS4 1/20 0.39
AR P10275 1/20 0.37
KMT2A Q03164 5/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
MEN1 O00255 2/20 0.35
TSHR P16473 1/20 0.35
CASP3 P42574 1/20 0.35
RAB9A P51151 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
GABRP O00591 2/20 0.34
GABRD O14764 2/20 0.34
GABRA1 P14867 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30873291 0.83 SIRT3 (0.42) ARKMT2AKDM4EMEN1
SCHEMBL21385773 0.81 HCAR2 (0.39) KDM6BKDM4AKDM4DHIF1ANKDM2A
SCHEMBL16612356 0.80 HSD11B1 (0.39) KDM6BKDM4AKDM4DHIF1ANKDM2A
SCHEMBL23094646 0.80 KMT2A (0.34) KMT2AL3MBTL1MEN1TSHRCASP3
SCHEMBL22473882 0.78 HCAR2 (0.36) KDM6BKDM4AKDM4DHIF1ANKDM2A
SCHEMBL1015260 0.78 HSD11B1 (0.50) KDM6BKDM4AKDM4DHIF1ANKDM2A
SCHEMBL19453386 0.78 KMT2A (0.33) ARKMT2ANPC1
SCHEMBL23094455 0.76 ALDH1A1 (0.49) KMT2AKDM4EL3MBTL1MEN1TSHR
SCHEMBL1667344 0.74 HPGD (0.47) KDM6BKDM4AKDM4DHCAR2KMT2A
SCHEMBL29364820 0.74 HPGD (0.47) KDM6BKDM4AKDM4DHCAR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10947206-B2 cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10947206-B2 cGAS antagonist compounds CGAS, STING1, GLS2 KDM6B 4648/4885KDM4A 4760/4885KDM4D 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.